<DOC>
	<DOCNO>NCT01232595</DOCNO>
	<brief_summary>This study ass safety efficacy multiple daily dose oral LFF571 patient moderate Clostridium difficile infection .</brief_summary>
	<brief_title>Safety Efficacy Multiple Daily Dosing Oral LFF571 Patients With Moderate Clostridium Difficile Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>Males females 18 90 year age , inclusive . Diagnosed primary episode first relapse moderate C. difficile infection . Received â‰¤24 hour therapy effective C. difficile infection prior enrollment . Severe C. difficile infection Expected require 10 day C. difficile infection treatment . More one prior episode C. difficile infection within prior 3 month . Use antiperistaltic drug ( include tincture opium , metoclopramide , loperamide ) , , cholestyramine , colestipol Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Clostridium difficile ,</keyword>
	<keyword>C. difficile ,</keyword>
	<keyword>CDI ,</keyword>
	<keyword>Clostridium difficile-associated disease ,</keyword>
	<keyword>CDAD ,</keyword>
	<keyword>pseudomembranous colitis ,</keyword>
	<keyword>PMC ,</keyword>
	<keyword>antibiotic-associated diarrhea</keyword>
</DOC>